Perturba Therapeutics Launches
Cyclica and Stagljar Lab have joined forces to launch Perturba Therapeutics, a neo-biotech project. Perturba will integrate Cyclica’s comprehensive AI-augmented proteome-wide drug design technology with the Stagljar Lab's first-in-class live cell-based assays to expand on the currently small subset of biologically important drug targets that are being explored within the pharma industry. Learn more.
EMI1: New EGFR-triple mutant inhibitor
Stagljar Lab is working on the further development of a novel EGFR-triple mutant inhibitor, named EMI1. EMI1 inhibits the signaling of EGFR-triple mutant lung cancer cells in a completely new way, leveraging molecular machineries to degrade mutated EGFR protein on the surface of tumor cells.
We hypothesize that EMI1’s complex mechanism of action will make it more difficult for lung tumors to develop resistance to it.
Fighting Covid-19 with SATiN
In only seven months, we developed an innovative and cost-effective COVID-19 serological test named SATiN (for Serological Assay based on split Tripart Nanoluciferase).
A description of this technology was published in Nature Communications and was featured in major TV segments and news media publications in Canada and abroad. Learn more.
SATiN Tests for Covid Variants
In collaboration with Shawn Owen’s lab at the University of Utah, the Stagljar lab has also recently further modified this split-luciferase assay so that it can be used to detect the presence and potency of neutralizing antibodies against SARS-CoV-2, including the wild-type and all major variants of concern.